The global HPAPIs and cytotoxic drugs manufacturing market is estimated to be valued at US$ 27.78 Bn in 2022 and is expected to exhibit a CAGR of 8.0% over the forecast period (2022-2030)
Figure 1: Global HPAPIs and Cytotoxic Drugs Manufacturing Market Share, (%), Analysis, By Drug Origin, 2022
Market players are indulged in inorganic activities such as collaboration, in order to enhance company’s product portfolio. This is expected to drive growth of the global HPAPIs and cytotoxic drugs manufacturing market over the forecast period.
Market players are engaged in the inorganic activities such as collaborations and this is expected to drive growth of the global HPAPIs and cytotoxic drugs manufacturing market over the forecast period. In April 2020, Trio Pharmaceuticals, Inc. and Ajinomoto Bio-Pharma Services announced a collaboration agreement to evaluate AJICAP, a proprietary site-specific conjugation technology offered by Aji Bio-Pharma for the development of TDCs (TRIObody Drug Conjugate). The AJICAP technology will be used to conjugate a cytotoxic payload to TRIO’s lead oncology candidate with TRIO evaluating functionality of the TDC.
Moreover, in March 2021, SEQENS, a company integrated in pharmaceutical synthesis and specialty ingredients announced a collaboration with RONDOL, a technology leader in the development and refinement of medication dosage extrusion technologies for formulation research and continuous manufacturing for more effective therapies and more efficient supply chains. The overall goal was to speed up the development and commercialization of extruded dosage forms with greater bioavailability, fewer adverse effects, and lower production costs.
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2021 | Market Size in 2022: | US$ 27.78 Bn |
Historical Data for: | 2018 to 2020 | Forecast Period: | 2022 to 2030 |
Forecast Period 2022 to 2030 CAGR: | 8.0% | 2030 Value Projection: | US$ 51.53 Bn |
Geographies covered: |
|